KDR and neoplasm: This vaccine demonstrated the ability to increase the population of M1 macrophages in the body and downregulate the expression of vascular endothelial growth factor receptor 2 (VEGFR2), further induced the production of specific antibodies against sEVs which weakened the pro-tumorigenic effects of PCDEVs, and inhibited tumor growth [162].